Search results for " 2016"
Article
Continuous Manufacturing: A Changing Processing Paradigm
GlaxoSmithKline’s new hybrid continuous-batch synthesis manufacturing plant in Jurong, Singapore—announced in October 2014 and predicted to open in 2016—cost 19 million euros (approximately $25 millio…
Article
USP Publishes Monoclonal Antibody Guidelines
…to become official in USP’s compendia of standards, USP 39–National Formulary (NF) 34, on May 1, 2016.
As individual product monographs will possibly describe specific quality attributes of indiv…
Article
High-Throughput Process Development in an Historical Environment
During the wrap-up of the meeting, there were several discussions about whether the HTPD meeting series should continue with a fourth event in 2016 or if HTPD today is such an established and mature a…
Article
Healthcare Reform in China
Chinese healthcare reforms may be a double-edged sword for foreign companies.
Sep 1, 2014
By: Jane Wan
BioPharm International
Volume 27, Issue 9, pp. 8-12
On March 25, 2014, the…
Article
Q&As with Industry Leaders
…;Cytiva
Bioprocessing Trends and Technologies at INTERPHEX 2016
Rita Peters, Editorial Director of BioPharm International
…
Article
Brazil Emerges as Global Biopharm Collaborator
By 2016, a year in which the country will host the Olympic Games, IMS estimates Brazil will occupy the fourth position, with an estimated growth between 1415%, only behind the US, China, and Japan and…
Article
Navigating Emerging Markets: Middle East and North Africa
Qatar has also announced plans to introduce a form of social health insurance by 2016.
Other countries in the region, including those much poorer than Qatar, have also begun working on increasi…
Article
Biosimilars Development and Supply: How Complex Can the Process Be?
Between 2005 and 2016, Amgen expects to invest approximately $1.5 billion in numerous strategies, including the geographic diversification of our capacity, to help ensure high-quality biologics get to…